Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department - Cagliari University (Italy)

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 11, 2012, Pages 1424-1430

  Atzori, L ^a   Pinna, A L ^a   Mantovani, L ^a   Ferreli, C ^a   Pau, M ^a   Mulargia, M ^a   Aste, N ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; AGED; ARTICLE; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRESS SYNDROME; DRUG ERUPTION; DRUG MONITORING; ERYTHRODERMA; FEMALE; FIXED DRUG ERUPTION; HOSPITALIZATION; HUMAN; HYPERURICEMIA; INCIDENCE; ITALY; LICHENOID ERUPTION; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PITYRIASIS ROSEA; PRESCRIPTION; PRIORITY JOURNAL; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VASCULITIS; WORLD HEALTH ORGANIZATION;

ALLOPURINOL; CROSS-SECTIONAL STUDIES; DATA COLLECTION; HOSPITAL DEPARTMENTS; HOSPITALS, UNIVERSITY; HUMANS; ITALY; SKIN;

EID: 84867576213     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04313.x     Document Type: Article

References (37)

1. Hunziker T, Künzi UP, Braunschweig S, et al. Comprehensive hospital monitoring (CMDH): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-393. (Pubitemid 27244150)
2. Wolkenstein P, Revuz J,. Drug-induced severe skin reactions. Incidence, management and prevention. Drug Saf 1995; 13: 56-68.
3. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J 2005; 35: 188-190.
4. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. JAAD 2008; 58: 25-32. (Pubitemid 350298142)
5. Russmann S, Lauterburg B,. Life-threatening adverse effects of pharmacologic antihyperuricemic therapy. Ther Umsch 2004; 61: 575-577. (Pubitemid 39237096)
6. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44. (Pubitemid 350249390)
7. Arellano F, Sacristán JA,. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 337-343. (Pubitemid 23086961)
8. Begon E, Roujeau JC,. Drug hypersensitivity syndrome: DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). Ann Dermatol Venereol 2004; 131: 293-297. (Pubitemid 38529545)
9. Hande KR, Noone RM, Stone WJ,. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56. (Pubitemid 14216359)
10. Emmerson BT, Hazelton RA, Frazer IH,. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum 1988; 31: 436-440. (Pubitemid 18091669)
11. Dalbeth N, Stamp L,. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007; 20: 391-395.
12. Chao J, Terkeltaub R,. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009; 11: 135-140.
13. Vázquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R,. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001; 60: 981-983. (Pubitemid 32885676)
14. Bocquet H, Bagot M, Roujeau JC,. Drug induced pseudolymphoma and drug hypersensitivity syndrome (DRSSS). Semin Cutan Med Surg 1996; 15: 250-257.
15. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist. Br J Dermatol 2007; 156: 609-611.
16. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124: 588-597.
17. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153. (Pubitemid 30637181)
18. Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-276. (Pubitemid 43323160)
19. Trent JT, Kirsner RS, Romanelli P, Kerdel FA,. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol 2004; 140: 890-892. (Pubitemid 38917869)
20. International drug monitoring: the role of national centres. Report of the WHO meeting. World Health Organ Rep Series 1972; 498: 1-25.
21. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-709.
22. Hung SI, Chung WH, Liou LB, et al. HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134-4139.
23. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
24. Draghi M, Yawata N, Gleimer M, et al. Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood 2005; 105: 2028-2035. (Pubitemid 40731788)
25. Chung WH, Hung SI,. Genetic markers and danger signals in Stevens-Johson syndrome and Toxic epidermal Necrolysis. Allergol Int 2010; 59: 325-332.
26. Braden GL, Warzynski MJ, Golightly M, Ballow M,. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994; 70: 145-151. (Pubitemid 24064942)
27. Halevy S, Cohen AD, Livni E,. The diagnostic role of the in vitro drug-induced interferon-gamma release test in Stevens-Johnson syndrome. Int J Dermatol 1999; 38: 835-840.
28. Britschgi M, Pichler WJ,. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002; 2: 325-331. (Pubitemid 36869641)
29. Lockard O Jr, Harmon C, Nolph K, Irvin W,. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med 1976; 85: 333-335.
30. Hamanaka H, Mizutani H, Nouchi N, et al. Allopurinol hypersensitivity syndrome: hypersensitivity to oxypurinol but not allopurinol. Clin Exp Dermatol 1998; 23: 32-34. (Pubitemid 28218196)
31. Young JL Jr, Boswell RB, Nies AS,. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med 1974; 134: 553-558.
32. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327. (Pubitemid 30149104)
33. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40. (Pubitemid 350298143)
34. Harr T, French LE,. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010; 5: 39.
35. Trent J, Halem M, French LE, Kerdel F,. Toxic epidermal necrolysis and intravenous immunoglobulin: a review. Semin Cutan Med Surg 2006; 25: 91-93. (Pubitemid 44189890)
36. Prins C, Kerdel FA, Padilla RS, et al. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32. (Pubitemid 36091570)
37. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493. (Pubitemid 28483679)